LOSS OF INSULIN-RECEPTOR IMMUNOREACTIVITY FROM THE SUBSTANTIA-NIGRA PARS-COMPACTA NEURONS IN PARKINSONS-DISEASE

被引:8
|
作者
MOROO, I
YAMADA, T
MAKINO, H
TOOYAMA, I
MCGEER, PL
MCGEER, EG
HIRAYAMA, K
机构
[1] CHIBA UNIV, SCH MED, DEPT NEUROL, 1-8-1 INOHANA, CHUO KU, CHIBA 260, JAPAN
[2] CHIBA UNIV, SCH MED, DIV INTERNAL MED 2, CHIBA, JAPAN
[3] SHIGA UNIV MED SCI, INST MOLEC NEUROBIOL, OTSU, SHIGA 52021, JAPAN
[4] UNIV BRITISH COLUMBIA, DEPT PSYCHIAT, KINSMEN LAB NEUROL RES, VANCOUVER V6T 1W5, BC, CANADA
[5] UNIV BRITISH COLUMBIA, CTR NEURODEGENERAT DIS, VANCOUVER V6T 1W5, BC, CANADA
关键词
PARKINSONS DISEASE; SUBSTANTIA-NIGRA INSULIN RECEPTOR; IMMUNOCHEMISTRY;
D O I
暂无
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Immunohistochemistry using both a newly developed polyclonal, and a commercially available monoclonal, anti-insulin receptor antibody was done on the midbrain from cases of idiopathic Parkinson's disease (PD), Alzheimer's disease, amyotrophic lateral sclerosis, vascular parkinsonism and non-neurological controls. Both antibodies gave identical patterns of neuronal staining. The neurons of the oculomotor nucleus were immunopositive in all the brains. However, the neurons in the pars compacta of the substantia nigra, paranigral nucleus, parabrachial pigmental nucleus, tegmental pedunculopontine nucleus, supratrocheal nucleus, cuneiform nucleus, subcuneiform nucleus and lemniscus medialis, which were positive in other diseases and in non-neurological controls, were not stained by these antibodies in PD brains. These results suggest that, in PD, a dysfunction of the insulin/insulin receptor system may precede death of the dopaminergic neurons.
引用
收藏
页码:343 / 348
页数:6
相关论文
共 50 条
  • [1] NEUROFILAMENT MESSENGER-RNA IS REDUCED IN PARKINSONS-DISEASE SUBSTANTIA-NIGRA PARS-COMPACTA NEURONS
    HILL, WD
    ARAI, M
    COHEN, JA
    TROJANOWSKI, JQ
    JOURNAL OF COMPARATIVE NEUROLOGY, 1993, 329 (03) : 328 - 336
  • [2] UNALTERED ACONITASE ACTIVITY, BUT DECREASED COMPLEX-I ACTIVITY IN SUBSTANTIA-NIGRA PARS-COMPACTA OF PATIENTS WITH PARKINSONS-DISEASE
    JANETZKY, B
    HAUCK, S
    YOUDIM, MBH
    RIEDERER, P
    JELLINGER, K
    PANTUCEK, F
    ZOCHLING, R
    BOISSL, KW
    REICHMANN, H
    NEUROSCIENCE LETTERS, 1994, 169 (1-2) : 126 - 128
  • [3] NEURONAL HYPERTROPHY IN THE PARS RETICULATA OF THE SUBSTANTIA-NIGRA IN PARKINSONS-DISEASE
    NEAL, JW
    PEARSON, RCA
    COLE, G
    POWELL, TPS
    NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY, 1991, 17 (03) : 203 - 206
  • [4] INCREASED IRON IN THE NEUROMELANIN-CONTAINING NEURONS IN THE SUBSTANTIA-NIGRA ZONA COMPACTA IN PARKINSONS-DISEASE
    CANDY, JM
    OAKLEY, AE
    MORRIS, CM
    LOVE, G
    PERROTT, H
    EDWARDSON, JA
    BRITISH JOURNAL OF PHARMACOLOGY, 1992, 107 : P71 - P71
  • [5] LOSS OF NONPHOSPHORYLATED NEUROFILAMENT IMMUNOREACTIVITY, WITH PRESERVATION OF TYROSINE-HYDROXYLASE, IN SURVIVING SUBSTANTIA-NIGRA NEURONS IN PARKINSONS-DISEASE
    GAI, WP
    VICKERS, JC
    BLUMBERGS, PC
    BLESSING, WW
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1994, 57 (09): : 1039 - 1046
  • [6] MEAN VOLUME OF PIGMENTED NEURONS IN THE SUBSTANTIA-NIGRA IN PARKINSONS-DISEASE
    MOLLER, A
    ACTA NEUROLOGICA SCANDINAVICA, 1992, 85 : 37 - 39
  • [7] LOSS OF BASIC FIBROBLAST GROWTH-FACTOR IN SUBSTANTIA-NIGRA NEURONS IN PARKINSONS-DISEASE
    TOOYAMA, I
    KAWAMATA, T
    WALKER, D
    YAMADA, T
    HANAI, K
    KIMURA, H
    IWANE, M
    IGARASHI, K
    MCGEER, EG
    MCGEER, PL
    NEUROLOGY, 1993, 43 (02) : 372 - 376
  • [8] COLLOID INCLUSIONS OF THE SUBSTANTIA-NIGRA IN PARKINSONS-DISEASE
    PAPPOLLA, MA
    DUDLEY, AW
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 1986, 86 (03) : 399 - 400
  • [9] IRON HISTOCHEMISTRY OF THE SUBSTANTIA-NIGRA IN PARKINSONS-DISEASE
    MORRIS, CM
    EDWARDSON, JA
    NEURODEGENERATION, 1994, 3 (04): : 277 - 282
  • [10] IRON (FE) AND ALUMINUM (AL) ACCUMULATE IN THE NEUROMELANIN GRANULES OF PIGMENTED NEURONS IN THE SUBSTANTIA-NIGRA PARS COMPACTA (SNC) OF IDIOPATHIC PARKINSONS-DISEASE (IPD)
    PERL, DP
    GOOD, PF
    OLANOW, CW
    JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 1992, 51 (03): : 327 - 327